TRANSMITTAL FORM (to be used for all correspondence after initial)	al filing)	U.S. Pate required to respond to a collect Application Number Filing Date First Named Inventor Group Art Unit Examiner Name	Appropriate Approp						
Total Number Of Pages In This Submission	10 + 12 Refs.	Attorney Docket No.	441472000110						
ENCLOSURES (check all that apply)									
Fee Transmittal Form Fee Attached Amendment / Reply After Final Affidavits/declarations Extension of Time Request Express Abandonment Request Information Disclosure Statement (3 pages)	Ass (for Dran Lice Peti Prov Chair Requirements)	ignment Papers an Application) wing(s) nsing-related Papers		After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): Form PTO-1449 (1 page in duplicate) 12 cited references International Search Report (4 pages) Return receipt postcard					
SIGNATULE Firm Morrison & Foerster LLF or Individual Name Cara M. Coburn, Reg. N Signature Date February 22, 2002	P, 755 Page N	PPLICANT, ATTORNE Mill Road, Palo Alto, CA 94304-1	EY OR AGE	NT					
CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"									

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on February 22, 2002.

Martina Placid

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

H. Ralph SNODGRASS

Serial No.:

09/864,621

Filing Date:

May 23, 2001

For:

TOXICITY TYPING USING

EMBRYOID BODIES

Examiner: To Be Assigned

Group Art Unit: 1633

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 AND § 1.98

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

The documents numbered 1-7 listed on the attached Form PTO-1449 were cited in Search Reports mailed on November 21, 2001 (copies attached) directed to related international applications. Please note the cited PCT publication No. WO 97/13877, as well as the cited articles "Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors," by N.S. Gray and "Automated Array Technologies for Gene Expression Profiling," by Maier et al. were not included on form 1449 as they were both cited in a previous Information Disclosure Statement submitted for the present Application

This Information Disclosure Statement is submitted:

\boxtimes	With	hin three months of the application filing date or before mailing of a first				
	Offic	Office Action on the merits; accordingly, no fee or separate requirements are				
	requi	red.				
	After	receipt of a first Office Action on the merits but before mailing of a final				
	Offic	Office Action or Notice of Allowance.				
		A fee is required. A check in the amount of * is enclosed.				
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is				
		attached to this submission in duplicate.				
		A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly;				
		no fee is believed to be due.				
	After	After mailing of a final Office Action or Notice of Allowance, but before paymen				
	of the	e issue fee.				
	\Box	A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in				
		the amount of * is enclosed.				
٠		A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee				
		Transmittal form (PTO/SB/17 is attached to this submission in duplicate.				

Applicant would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

 \square

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 441472000110. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: February 22, 2002

Respectfully submitted,

Registration No. 46,631

Morrison & Foerster LLP 755 Page Mill Road

Palo Alto, California 94304-1018

Telephone: (650) 813-4218 Facsimile: (650) 494-0792

Form PTO-1449			Docket Number 441472000110		Application Number 09/864,621				
INFORMATION DISCLOSURE CITATION			Applicant H. Ralph SNODGRASS			•			
IN AN APPLICATION					H. Kaiph S	T	ੁ	<u> </u>	
A F	PE Cuse several sheets if necessary)			Filing Date May 23, 2001 Group Art Unit 1633				_ \	
O ME PAI				Filing Date May 23, 2001 Group Art Unit 1633 A A TOOCLIMENTS					
MARO	3 10							16	32 1
<i>Y</i> •	- ARX	7						95	2002
ATENT 8	TRADE		U.S. PAT	ΓEN	T DOCUMENTS			<u>1900</u>	
Examiner Initials	Ref. No.	Date	Document No.		Name	Class	Subclass	Filing I Appro	
	1.	11/19/1996	5,576,207	Rei	d et al.				
	2.	09/22/1998	5,811,297	Go	pal		 .		
	Ļ <u></u> _		1-,,-	<u> </u>			<u></u>		
l			FOREIGN I	TAS	ENT DOCUMEN	ITS			
Examiner Initials	1 1			Country	Class	Subclass	Transl YES	ation NO	
	3.	03/04/1999	WO 99/10535 A1	W	PO				
	4.	05/14/1999	WO 99/23254 A1	W	PO				
	5.	06/03/1999	WO 99/27090 A1	W	PO				
	6.	09/02/1999	WO 99/44062 A1	W	PO				
	7.	05/25/2000	WO 00/29002 A2,3	W	IPO	·			
			OTHE	R D	OCUMENTS	(includ	ing author, title, D	ate, Pertinent l	Pages, Etc.)
Examiner Initials	Examiner Ref. Title								
	8. Flint, O.P. (1998). "Predicting In Vivo Toxicity," Toxicology in Vitro 12:591-595.								
	 Ling, V. and S. Neben. (1997). "In Vitro Differentiation of Embryonic Stem Cells: Immunophentypic Analysis of Cultured Embryoid Bodies," J. Cell. Physiology 171:104-115. Matsui et al. (1992) "Derivation of Pluripotential Embryonic Stem Cells from Murine Primordial Germ Cells in Culture," Cell 70:841-847. Seamark, R.F. (1994). "Progress and Emerging Problems in Livestock Transgenesis: A Summary Perspective," Reprod. Fertil. Dev. 6:653-657. 							hentypic	
								dial	
								nary	
	12. Spielmann et al. (1997). "The Ebryonic Stem Cell Test, an <i>In Vitro</i> Embryotoxicity Test Using Two Permanent Mouse Cell Lines: 3T3 Fibroblasts and Embryonic Stem Cells," <i>In Vitro Toxicology</i> 10(1):119-127.								ng Two gy
EXAMINER:			DATE CONSIDERED:						
EXAMII	NER: Init	tial if citation con	sidered, whether or not th	e cita	tion conforms with MP	EP 609. Draw applicant.	a line through th	e citation if n	ot in